ProBioGen has inked a multi-product commercial license agreement with AstraZeneca to use the GlymaxX technology.
Following evaluation of the technology under a research license, AstraZeneca will now continue to use GlymaxX and will integrate the technology into their drug discovery.
GlymaxX improves target cell killing orchestrated by natural killer cells, thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). It is a universal, simple technology that allows modifying existing cell lines or creating new ones, demonstrating its flexibility. Another unique advantage of GlymaxX is that it allows using the same modified cell line to produce antibodies of varying levels of fucosylation.
ProBioGen’s Chief Business Officer, Dr Gabriele Schneider, said: “We are delighted that AstraZeneca decided to implement our technology, which has shown great potential in making molecules more potent and efficient.”